Omeq Medical, part of The Trendlines Group, has obtained regulatory approval from the US Food and Drug Administration (FDA) for its EpiFinder device that helps physicians precisely place an epidural needle while conducting the standard Loss of Resistance (LOR) technique.

EpiFinder is capable of providing physicians with an added signal recognising the epidural space.

It is a sensor-driven, battery-operated single-use epidural placement device that can be used for safe, accurate epidural injections.

Users can place the device between a standard needle and a syringe. It eliminates the need for capital equipment and is compatible with the existing epidural syringes.

EpiFinder also has the capability to monitor tissue resistance at the needle tip to accurately identify penetration of the needle into the epidural space, thereby safeguarding the patient from complications arising out of misplacement.

In a first-in-human clinical trial conducted by Omeq to show the safety and effectiveness of EpiFinder, it was found that the device can be safely used to accurately position an epidural needle.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Using EpiFinder, physicians of the trial were able to securely provide successful epidural blocks in all 31 patients.

Omeq Medical CEO Lior Margalit said: “We now turn our focus to bring EpiFinder to US patients receiving epidural injections.

“EpiFinder offers the potential to become the new standard of care while performing LOR. The procedure today is performed by advancing the epidural needle forward until the clinician senses a loss of resistance indicating that the epidural space in the spine has been reached.

“Using the same procedure, EpiFinder adds a second independent objective signal that the epidural space has been reached. Our initial clinical experience indicates that clinicians’ targeting and placement are accurate with the EpiFinder.”